Publications by authors named "Suzanne Lukac"
Background: Single-cell network profiling (SCNP) is a multiparametric flow cytometry-based approach that simultaneously measures evoked signaling in multiple cell subsets. Previously, using the SCNP approach, age-associated immune signaling responses were identified in a cohort of 60 healthy donors.
Methods: In the current study, a high-dimensional analysis of intracellular signaling was performed by measuring 24 signaling nodes in 7 distinct immune cell subsets within PBMCs in an independent cohort of 174 healthy donors [144 elderly (>65 yrs); 30 young (25-40 yrs)].
Article Synopsis
- The study aimed to assess the bunionectomy model for evaluating various analgesics beyond opioids and NSAIDs.
- Pregabalin and naproxen sodium were tested against a placebo in a randomized trial with 100 patients to measure their impact on postoperative pain management.
- Both pregabalin and naproxen significantly reduced opioid consumption and increased the time until first opioid use, with naproxen showing a greater overall effectiveness in pain relief compared to pregabalin.
Objective: Administration of a quadrivalent HPV-6/ 1/16/18 vaccine to 16- to 26-year-old women was highly effective in preventing HPV-6/ 1/16/18-related cervical/vulvar/vaginal precancerous lesions and genital warts. As the risk of acquiring HPV significantly rises after sexual debut, HPV vaccines should have the greatest benefit in sexually naive adolescents. We evaluated the tolerability and immunogenicity of quadrivalent vaccine in males and females 9 to 15 years of age through 18 months postenrollment.
View Article and Find Full Text PDFObjective: Prophylactic vaccination of 16- to 23-year-old females with a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine has been shown to prevent type-specific human papillomavirus infection and associated clinical disease. We conducted a noninferiority immunogenicity study to bridge the efficacy findings in young women to preadolescent and adolescent girls and boys, who represent a primary target for human papillomavirus vaccination.
Methods: We enrolled 506 girls and 510 boys (10-15 years of age) and 513 females (16-23 years of age).